{
    "organizations": [],
    "uuid": "06c056bf5047b05cce20310879cc8ca055686269",
    "author": "",
    "url": "https://www.reuters.com/article/brief-selecta-biosciences-presents-new-d/brief-selecta-biosciences-presents-new-data-from-ongoing-phase-2-trial-of-sel-212-in-development-for-chronic-severe-gout-idUSFWN1RN0MC",
    "ord_in_thread": 0,
    "title": "BRIEF-Selecta Biosciences Presents New Data From Ongoing Phase 2 Trial Of Sel 212 In Development For Chronic Severe Gout",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Market News  42 PM / Updated 12 minutes ago BRIEF-Selecta Biosciences Presents New Data From Ongoing Phase 2 Trial Of Sel 212 In Development For Chronic Severe Gout Reuters Staff \nApril 10 (Reuters) - Selecta Biosciences Inc: \n* 212, IN DEVELOPMENT FOR CHRONIC SEVERE GOUT, AT PANLAR 2018 CONGRESS \n* 212 PRODUCT PROFILE MAY PROVIDE BETTER AND MORE SUSTAINED SERUM URIC ACID CONTROL \n* 212 GENERALLY WELL TOLERATED AT CLINICALLY ACTIVE DOSES FOLLOWING REPEATED ADMINISTRATIONS IN ONGOING PHASE 2 TRIAL \n* 212 IS EXPECTED TO START LATER IN 2018 Source text for Eikon: Further company coverage:",
    "published": "2018-04-10T15:41:00.000+03:00",
    "crawled": "2018-04-10T16:00:39.000+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "market",
        "news",
        "pm",
        "updated",
        "minute",
        "ago",
        "bioscience",
        "present",
        "new",
        "data",
        "ongoing",
        "phase",
        "trial",
        "sel",
        "development",
        "chronic",
        "severe",
        "gout",
        "reuters",
        "staff",
        "april",
        "reuters",
        "selecta",
        "bioscience",
        "inc",
        "development",
        "chronic",
        "severe",
        "gout",
        "panlar",
        "congress",
        "product",
        "profile",
        "may",
        "provide",
        "better",
        "sustained",
        "serum",
        "uric",
        "acid",
        "control",
        "generally",
        "well",
        "tolerated",
        "clinically",
        "active",
        "dos",
        "following",
        "repeated",
        "administration",
        "ongoing",
        "phase",
        "trial",
        "expected",
        "start",
        "later",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}